Compare Amylx Pharmaceuticals Inc (AMLX) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Global X NASDAQ 100 Covered Call ETF trades at $18.16. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Global X NASDAQ 100 Covered Call ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | QYLD | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $24.19 | $18.52 |
52-Week Low | $7.82 | $16.46 |
Enterprise Value | $2.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
QYLD trades at $18.18, up 0.14% on the day, with a bullish technical signal from moving averages but bearish oscillators. The ETF offers a high distribution yield near 12% through covered call strategies on the Nasdaq-100, though historical data shows it has underperformed the index in strong bull markets. Recent dividends include $0.18 and $0.19 payouts in mid-2026.
Outlook is mixed: QYLD provides substantial income for risk-averse investors in sideways markets, but caps upside potential. Key risks include erosion of net asset value during rallies and competition from lower-fee alternatives. Analyst sentiment is divided, with some upgrades highlighting yield appeal amid volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
